Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly ... efforts to expand our diabetes portfolio and provide high quality, affordable health care to our patients," Nilesh ...

Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has been ...

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly ... our diabetes portfolio and provide high-quality, affordable health care to our ...

This week, Ashley and I are attending the annual JPMorgan Health Care Conference ... costs. Eli Lilly on Tuesday cut its revenue guidance as it said demand for its weight loss and diabetes ...